Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Radiotherapy in Combination With Chemotherapy and Immunotherapy in Patients With PD-L1-Positive Metastatic Triple-Negative Breast Cancer

NCT05233696 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT05233696
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05233696 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Radiotherapy in Combination With Chemotherapy and Immunotherapy in Patients With PD-L1-Positive Metastatic Triple-Negative Breast Cancer
Lead sponsor
University of Colorado, Denver
Phase
Phase 2
Overall status
Withdrawn
Start date
January 4, 2022
Completion date
December 1, 2022
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced breast cancer, metastatic breast cancer, pd-l1 gene mutation, triple negative breast cancer, unresectable breast carcinoma